Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This 2 arms study will compare the efficacy and safety of treatment with sequential erlotinib
plus docetaxel therapy versus docetaxel alone as second line treatment in patients with
recurrent non-small cell lung cancer. Patients will be randomized to receive in group
1(experimental arm): docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per
os d2-d16 and group 2 (control arm): docetaxel :75 mg/m² IV day 1 every 3 weeks.
The anticipated time on study treatment is until disease progression. Target sample size is
156.
The main of this study is to determine the relevance of the association sequential erlotinib
and docetaxel in terms of progression-free survival .